Skip to main
KNW
KNW logo

KNW Stock Forecast & Price Target

KNW Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Know Labs, Inc. operates within a rapidly growing healthcare system, which experienced a significant increase from $245 billion in 2012 to $327 billion in 2017, reflecting a 26% growth over five years, equating to a 6% compound annual growth rate (CAGR). The company's innovative Bio-RFID and ChromaID technologies, particularly the development of a non-invasive blood glucose monitoring wearable device, position it to capture unmet market needs, especially given the renewed focus on metabolism and weight management. Furthermore, the potential revenue streams from international markets and non-insulin-using Type 2 diabetes patients present substantial growth opportunities that are not currently accounted for in profit expectations, indicating a positive outlook for future financial performance.

Bears say

Know Labs Inc. has faced persistent operating losses since its inception, raising concerns about its potential to achieve profitability in the near future. Additionally, the company faces significant competitive pressures from existing therapies and procedures that could hinder product adoption and overall performance. The negative sentiment surrounding Know Labs is compounded by the emergence of GLP-1 agonists, which may reduce the patient population for diabetes management, further impacting the company's market prospects.

KNW has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Know Labs Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Know Labs Inc (KNW) Forecast

Analysts have given KNW a Buy based on their latest research and market trends.

According to 1 analysts, KNW has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Know Labs Inc (KNW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.